143 related articles for article (PubMed ID: 33408315)
21. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
[TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
[TBL] [Abstract][Full Text] [Related]
23. Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).
He W; Cao M; Li Z
Drug Dev Res; 2020 Aug; 81(5):551-556. PubMed ID: 32142170
[TBL] [Abstract][Full Text] [Related]
24. Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction.
Owolabi US; Amraotkar AR; Coulter AR; Singam NSV; Aladili BN; Singh A; Trainor PJ; Mitra R; DeFilippis AP
J Thromb Thrombolysis; 2020 Feb; 49(2):235-244. PubMed ID: 31808123
[TBL] [Abstract][Full Text] [Related]
25. Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction.
Fujiwara T; Matsunaga T; Kameda K; Abe N; Ono H; Higuma T; Yokoyama J; Hanada H; Osanai T; Okumura K
Heart Vessels; 2007 Sep; 22(5):303-9. PubMed ID: 17879021
[TBL] [Abstract][Full Text] [Related]
26. [Correlation between serum MMP-2 and MMP-9 in patients with acute myocardial infarction before and after PCI].
Dai F; Xiao GL; Pan J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Aug; 25(8):716-8. PubMed ID: 19664397
[TBL] [Abstract][Full Text] [Related]
27. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
[TBL] [Abstract][Full Text] [Related]
28. Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial.
Fonseca FAH; Izar MC; Maugeri IML; Berwanger O; Damiani LP; Pinto IM; Szarf G; França CN; Bianco HT; Moreira FT; Caixeta A; Alves CMR; Soriano Lopes A; Klassen A; Tavares MFM; Fonseca HA; Carvalho ACC;
Trials; 2017 Dec; 18(1):601. PubMed ID: 29258572
[TBL] [Abstract][Full Text] [Related]
29. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.
Fukuda D; Shimada K; Tanaka A; Kusuyama T; Yamashita H; Ehara S; Nakamura Y; Kawarabayashi T; Iida H; Yoshiyama M; Yoshikawa J
Am J Cardiol; 2006 Jan; 97(2):175-80. PubMed ID: 16442358
[TBL] [Abstract][Full Text] [Related]
30. Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).
Shimomura M; Oyama J; Takeuchi M; Shibata Y; Yamamoto Y; Kawasaki T; Komoda H; Kodama K; Sakuma M; Toyoda S; Inoue Y; Mine D; Natsuaki M; Komatsu A; Hikichi Y; Yamagishi S; Inoue T; Node K
Heart Vessels; 2016 Oct; 31(10):1583-9. PubMed ID: 26699899
[TBL] [Abstract][Full Text] [Related]
31. Predictive utility of the changes in matrix metalloproteinase-2 in the early phase for left ventricular reverse remodeling after an acute myocardial infarction.
Morishita T; Uzui H; Mitsuke Y; Arakawa K; Amaya N; Kaseno K; Ishida K; Nakaya R; Lee JD; Tada H
J Am Heart Assoc; 2015 Jan; 4(1):e001359. PubMed ID: 25616975
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
[TBL] [Abstract][Full Text] [Related]
33. Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study.
Godino C; Pavon AG; Mangieri A; Salerno A; Cera M; Monello A; Chieffo A; Magni V; Cappelletti A; Margonato A; Colombo A
Clin Cardiol; 2017 Aug; 40(8):605-611. PubMed ID: 28422300
[TBL] [Abstract][Full Text] [Related]
34. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
35. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care.
Colivicchi F; Gulizia MM; Franzini L; Imperoli G; Castello L; Aiello A; Ripellino C; Cataldo N
Adv Ther; 2016 Nov; 33(11):2049-2058. PubMed ID: 27671328
[TBL] [Abstract][Full Text] [Related]
37. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.
Kelly D; Cockerill G; Ng LL; Thompson M; Khan S; Samani NJ; Squire IB
Eur Heart J; 2007 Mar; 28(6):711-8. PubMed ID: 17339265
[TBL] [Abstract][Full Text] [Related]
38. Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction.
Hioki H; Motoki H; Izawa A; Kashima Y; Miura T; Ebisawa S; Tomita T; Miyashita Y; Koyama J; Ikeda U
Heart Vessels; 2016 May; 31(5):687-93. PubMed ID: 25863805
[TBL] [Abstract][Full Text] [Related]
39. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.
Roy D; Mahapatra T; Manna K; Kar A; Rana MS; Roy A; Bose PK; Banerjee B; Paul S; Chakraborty S
PLoS One; 2020; 15(5):e0233230. PubMed ID: 32428019
[TBL] [Abstract][Full Text] [Related]
40. Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction.
Kaden JJ; Dempfle CE; Sueselbeck T; Brueckmann M; Poerner TC; Haghi D; Haase KK; Borggrefe M
Cardiology; 2003; 99(3):140-4. PubMed ID: 12824721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
